2024年9月27日,康哲药业(00867)股价盘中一度大涨6.77%,报8.55港元,引发市场关注。推动康哲药业股价上涨的主要原因有以下几点:
首先,康哲药业近期业绩表现亮眼。最新的财报数据显示,该公司实现营业收入39.57亿港元,净利润9.98亿港元,每股收益0.41港元,毛利达29.54亿港元。基于良好的财务数据,该股获得了10家机构一致的买入评级,反映出市场对公司长期发展前景的看好。
其次,大量资金持续流入该股。27日当天,康哲药业主力资金净流入193万港元,延续了连续3日净流入的态势,显示机构投资者对这只潜力股青睐有加。数据显示,近5日和20日该股主力资金累计净流入金额分别高达2146万元和1256万元,充分彰显了资金对这只股票的持续看好。
此外,公司所属药品行业整体向好,当日板块上涨0.63%,相关个股亦有不俗表现。部分药品股表现出色,如艾美疫苗、凯莱英、联康生物等股价涨幅超5%,带动了行业板块的走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.